Regular Delivery Service, let us remember for you!

Vetmedin for Dogs

Vetmedin for Dogs
1.25mg Flavour Tablet » Pack of 100
5mg Capsule » Pot of 100
5mg Flavour Tablet » Pack of 50
10mg Flavour Tablet » Priced per Tablet
Solution 0.75mg/ml 5ml Injection

  • 1.25mg Flavour Tablet » Pack of 100 £25.99
  • 1.25mg Flavour Tablet » Priced per Tablet £0.29
  • 5mg Capsule » Pot of 100 £52.00
  • 5mg Capsule » Priced per Capsule £0.59
  • 5mg Flavour Tablet » Pack of 50 £39.49
  • 5mg Flavour Tablet » Priced per Tablet £0.79
  • 10mg Flavour Tablet » Priced per Tablet £1.49
  • Solution 0.75mg/ml 5ml Injection £30.49

Selection of 8 products from

£0.29 to £52.00

Description

Vetmedin is a pet medication which can open up the main blood vessels to the heart to reduce the pressure. It can also make the heart work more efficiently and clinical studies indicate that this can increase life expectancy. This medication is commonly used to treat heart failure in dogs. Dogs may need to take this medication for the rest of their lives though improvements can usually be seen in a few days. The medication is available in different strengths for different sized animals and is in the form of chewable tablets so it is easy to administer.

Vetmedin is used mostly in dogs with defective heart valves. (Valvular insufficiency or regurgitation, often as a result of nodular endocardiosis.) If the valves in the heart fail to operate properly, blood flows back when the valves is supposed to be closed, making the heart less efficient as a pump. This also makes a whooshing sound in the heart, called a heart murmur, which vets can hear using a stethoscope. Vetmedin acts on the muscle of the heart and of blood vessel walls, helping the heart to beat more efficiently.

Vetmedin is also used to treat heart problems where the muscle has become stretched and weak (dilated cardiomyopathy). The heart muscle can contract more powerfully, improving circulation to the body tissues. Vetmedin can be used on its own, but usually one or more other drugs are used to add edto increase the beneficial effects.

Vetmedin is not suitable for dogs under the age of six months and should not be given to pregnant or nursing dogs. Care should also be taken with animals suffering from conditions such as diabetes and who are already taking other medications. Your vet will be able to determine if there is a risk of interactions with any other pet medication.

Vetmedin can only be obtained with a prescription from the vet. Buying prescription pet meds online still requires a written prescription, which must be sent with the order before the drugs can be supplied.

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

5mg Capsule » Priced per Capsule

Vetmedin 5 mg hard capsules

Presentation

Hard capsules white to orange in colour, containing 5 mg pimobendan per capsule as active substance and titanium Dioxide (E171) 1.2320 mg/capsule and Sunset Yellow (E110) 0.3080 mg/capsule as excipients.

Uses

For the treatment of canine congestive heart failure originating from valvular insufficiency (mitral and/or tricuspid regurgitation) or dilated cardiomyopathy.

When used in cases of valvular insufficiency in conjunction with frusemide, the product has been shown to improve the quality of life and extend life expectancy in treated dogs.

When used in a limited number of cases of dilated cardiomyopathy in conjunction with frusemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.

Dosage and administration

See dosing table below.

Vetmedin capsules should be administered orally (approximately one hour before feeding) at a dose of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The daily dose should be divided into two equal administrations, one half of the dose given in the morning and the other half approximately 12 hours later.

Determine the bodyweight accurately before prescribing to ensure administration of the correct dosage.

In cases of mild congestive heart failure, a daily dosage at the lower end of the dose range may be adequate. If, however, a clear response is not observable within one week, the dosage should be raised.

Vetmedin capsules may be combined with a diuretic treatment such as frusemide.

Contra-indications, warnings, etc

Vetmedin capsules should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis).

Special precautions for use in animals

The product should only be used in dogs with cardiac insufficiency. Do not exceed the recommend dosage.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed.

In studies with rats and rabbits, pimobendan had no effect on fertility and embryotoxic effects occurred only at maternotoxic doses. In experiments with rats it has been shown that pimobendan is excreted into milk.

No information is available on the safety of Vetmedin in pregnant and lactating bitches. Therefore, Vetmedin capsules should only be administered to pregnant and lactating bitches if the expected therapeutic benefits outweigh the potential risk.

The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β-antagonist propranolol. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected.

In the case of overdose, symptomatic treatment should be initiated.

Pharmaceutical precautions

Shelf life of the veterinary medicinal product as packaged for sale : 3 years.

Do not store above 25°C. Store in a dry place. Store in tightly closed original container.

Keep out of the reach and sight of children. For animal treatment only.

To be supplied only on veterinary prescription.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Legal category

Packaging quantities

Vetmedin 5.0 mg capsules are presented in white high density polyethylene bottles with white polypropylene child-resistant screw-caps OR white polypropylene bottle with white polypropylene child resistant screw-caps. Each bottle contains 100 capsules and is packed in a cardboard carton. Not all presentations may be marketed.

Further information

Pharmacodynamic properties

Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties. Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity. The combined evidence from cell culture, laboratory animal and small studies in the target species suggests that the combination of the specific PD properties of pimobendan may reduce the progression of myocardial damage in dogs with MVD and DCM when used together with other standard therapy.

Pharmacokinetic particulars

Absorption Following oral administration of Vetmedin capsules the absolute bioavailability of the active principle is 60 – 63%. Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.

Distribution The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93%

Metabolism The compound is oxidatively demethylated to its major active metabolite (UD-CG 212). Further metabolic pathways are phase II conjugates of UD-CG-212, in essence glucuronides and sulphates.

Elimination The plasma elimination half-life of pimobendan is 0.4±0.1 hours which is consistent with a high clearance of 90±19 ml/min/kg and a short mean residence time of 0.5 ± 0.1hours.

The main active metabolite is eliminated with a plasma elimination half-life of 2.0 ± 0.3 hours. Almost the entire dose is eliminated via faeces.

Marketing Authorisation Number

Vm 00015/4050

1.25mg Flavour Tablet » Priced per Tablet

Vetmedin Chew 1.25 mg, 5 mg and 10 mg chewable tablets for dogs

Presentation

Chewable tablet.

Brownish, oval, divisible tablet, scored on both sides.

One 1.25 mg chewable tablet contains 1.25 mg pimobendan as active substance.

One 5 mg chewable tablet contains 5 mg pimobendan as active substance.

One 10 mg chewable tablet contains 10 mg pimobendan as active substance.

The tablets can be divided into equal parts.

Uses

For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regurgitation) (See section 'Dosage and administration').

For the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter) in Doberman Pinschers following echocardiographic diagnosis of cardiac disease (see section 'Contra-indications, warnings, etc').

For the treatment of dogs with myxomatous mitral valve disease (MMVD) in the preclinical stage (asymptomatic with a systolic mitral murmur and evidence of increased heart size) to delay the onset of clinical symptoms of heart failure (see section 'Contra-indications, warnings, etc').

Dosage and administration

Determine the bodyweight accurately before treatment to ensure correct dosage.

A dosage range of 0.2 mg to 0.6 mg pimobendan/kg body weight, divided into two daily doses, should be respected.

The preferable daily dose is 0.5 mg pimobendan/kg body weight, divided into two daily doses.

For a body weight of 5 kg, this corresponds to one 1.25 mg chewable tablet in the morning and one 1.25 mg chewable tablet in the evening.

For a body weight of 20 kg, this corresponds to one 5 mg chewable tablet in the morning and one 5 mg chewable tablet in the evening.

For a body weight of 40 kg, this corresponds to one 10 mg chewable tablet in the morning and one 10 mg chewable tablet in the evening.

Do not exceed the recommended dosage.

Pimobendan is orally administered. Administration of pimobendan should take place approximately one hour before feeding.

Pimobendan may also be used in combination with a diuretic, e.g. furosemide.

To allow accurate dosing according to body weight, the chewable tablet can be halved along the designated score line.

Contra-indications, warnings, etc

Do not use pimobendan in hypertrophic cardiomyopathies or in diseases in which an improvement in cardiac output cannot be achieved for functional or anatomical reasons (e.g. aortic stenosis). Since pimobendan is metabolised mainly via the liver, it should not be used in dogs with severe impairment of liver function.

The product has not been tested in cases of asymptomatic DCM in Dobermans with atrial fibrillation or sustained ventricular tachycardia.

The product has not been tested in cases of asymptomatic myxomatous mitral valve disease in dogs with significant supraventricular and/or ventricular tachyarrhythmia.

The blood glucose should be tested regularly during treatment in dogs with existing diabetes mellitus.

For use in the “preclinical stage” of dilated cardiomyopathy (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter), a diagnosis should be made by means of a comprehensive cardiac examination (incl. echocardiographic examination and possibly Holter monitoring).

For use in the preclinical stage of myxomatous mitral valve disease (stage B2, according to ACVIM consensus: asymptomatic with mitral murmur ≥3/6 and cardiomegaly due to myxomatous mitral valve disease), a diagnosis should be made by means of a comprehensive physical and cardiac examination which should include echocardiography or radiography where appropriate. (See also 'Further Information' section).

Monitoring of cardiac function and morphology is recommended in animals treated with pimobendan.

The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of animals.

In rare cases a slight positively chronotropic effect (rise in heart rate) and vomiting can occur. However, these effects are dose-dependent and can be avoided by reducing the dose.

In rare cases transient diarrhoea, anorexia or lethargy have been observed.

In rare cases, an increase in mitral valve regurgitation has been observed during chronic pimobendan treatment in dogs with mitral valve disease.

Although a relationship with pimobendan has not been clearly established, in very rare cases, signs of effects on primary haemostasis (petechiae on mucous membranes, subcutaneous haemorrhages) may be observed during treatment. These signs disappear when the treatment is withdrawn.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Laboratory studies in rats and rabbits have not produced any evidence of teratogenic or foetotoxic effects. However, these studies have shown evidence of maternotoxic and embryotoxic effects at high doses, and have also shown that pimobendan is excreted into milk. The safety of the product has not been assessed in pregnant or nursing bitches. Use only according to the benefit/risk assessment by the responsible veterinarian.

In pharmacological studies no interaction between the cardiac glycoside strophanthin and pimobendan was observed. The pimobendan-induced increase in cardiac contractility is attenuated by the calcium antagonists verapamil and diltiazem and by the β-antagonist propranolol.

An overdose may cause a positive chronotropic effect, vomiting, apathy, ataxia, heart murmurs or hypotension. In this situation, the dosage should be reduced and appropriate symptomatic treatment should be initiated.

In prolonged exposure (6 months) of healthy beagle dogs at 3 and 5 times the recommended dose, mitral valve thickening and left ventricular hypertrophy were observed in some dogs. These changes are of pharmacodynamic origin.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

Advice to doctors: accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches.

Pharmaceutical precautions

Shelf life of the veterinary medicinal product as packaged for sale: 30 months

Shelf life of the divided (halved) tablets after opening the immediate packaging: 3 days

Do not store above 25°C.

Divided tablets should be returned to the open blister pocket and placed back in the cardboard box.

Keep out of sight and reach of children. For animal treatment only.

To be supplied only on veterinary prescription.

Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Legal category

Packaging quantities

Heat sealed Aluminium// PVC/ Aluminium/ Polyamide blister strip containing 10 tablets.

Cardboard box with 2 blister strips of 10 tablets (20 tablets)

Cardboard box with 5 blister strips of 10 tablets (50 tablets)

Cardboard box with 10 blister strips of 10 tablets (100 tablets)

Not all packs sizes may be marketed.

Marketing Authorisation Holder (if different from distributor)

Further information

Pimobendan, a benzimadazole-pyridazinone derivative has a positively inotropic action and possesses pronounced vasodilator properties.

The positive inotropic effect of pimobendan is mediated by two action mechanisms: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase III. Thus the positive inotropism is triggered neither by an action similar to that of the cardiac glycosides nor sympathomimetically.

The vasodilator effect arises from inhibition of phosphodiesterase III.

When used in cases of symptomatic valvular insufficiency in conjunction with furosemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs.

When used in a limited number of cases of symptomatic dilated cardiomyopathy in conjunction with furosemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.

In a randomized and placebo controlled study in 363 dogs with preclinical myxomatous mitral valve disease, all dogs met the following inclusion criteria: age ≥ 6 years, bodyweight ≥ 4.1 and ≤ 15 kg, characteristic systolic heart murmur of moderate to high intensity (≥grade 3/6) with maximal intensity over the mitral area; echocardiographic evidence of advanced myxomatous mitral valve disease (MMVD) defined as characteristic valvular lesions of the mitral valve apparatus, echocardiographic evidence of left atrial and left ventricular dilatation and radiographic evidence of cardiomegaly (vertebral heart sum (VHS) > 10.5. The median time to onset of clinical signs of heart failure or cardiac death/euthanasia was extended in these dogs by approximately 15 months. Additionally, there was a reduction in the heart size of dogs treated with pimobendan in the preclinical stage of myxomatous mitral valve disease. Furthermore, overall survival time was prolonged by approximately 170 days in all dogs receiving pimobendan independent of their cause of death (cardiac death/ euthanasia and non-cardiac death/euthanasia). Cardiac related death or euthanasia occurred in 15 dogs in the pimobendan group and 12 dogs in the placebo group prior to the onset of CHF. Dogs in the pimobendan group spent a longer time in the study (347.4 patient years) than those in the placebo group (267.7 patient years) resulting in a lower rate of occurrence.

In a randomized and placebo controlled study including Doberman Pinschers with preclinical dilated cardiomyopathy (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter following echocardiographic diagnosis), the time to onset of congestive heart failure or sudden death was extended and survival time was prolonged among dogs administered pimobendan.

Additionally, there was a reduction in the heart size of dogs treated with pimobendan in the preclinical stage of dilated cardiomyopathy. Efficacy evaluation is based on data from 19 (of 39) and 25 (of 37) dogs that reached the primary efficacy endpoint in the pimobendan and the placebo group, respectively.

Absorption: After oral administration of this veterinary medicinal product the absolute bioavailability of its active substance is 60 - 63%. Since simultaneous or previous food intake reduces the bioavailability, pimobendan should be administered about 1 hour before feeding.

Distribution: The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93%.

Metabolism: The compound is demethylated by oxidation to the major active metabolite (UD-CG212). Further metabolic steps are phase II conjugates of UD-CG212, such as glucuronides and sulphates.

Elimination:The plasma elimination half-life of pimobendan is 0.4 ± 0.1 hours, which corresponds to the high clearance of 90 ± 19 ml/min/kg and the short mean residence of 0.5 ± 0.1 hours.

The most significant active metabolite is eliminated with a plasma elimination half-life of 2.0 ± 0.3 hours. Almost the entire dose is eliminated in the faeces.

Marketing Authorisation Number

Vetmedin Chew 1.25 mg chewable tablets for dogs: Vm 00015/4091

Vetmedin Chew 5 mg chewable tablets for dogs: Vm 00015/4093

Vetmedin Chew 10 mg chewable tablets for dogs: Vm 00015/4094

5mg Flavour Tablet » Priced per Tablet

Vetmedin Chew 1.25 mg, 5 mg and 10 mg chewable tablets for dogs

Presentation

Chewable tablet.

Brownish, oval, divisible tablet, scored on both sides.

One 1.25 mg chewable tablet contains 1.25 mg pimobendan as active substance.

One 5 mg chewable tablet contains 5 mg pimobendan as active substance.

One 10 mg chewable tablet contains 10 mg pimobendan as active substance.

The tablets can be divided into equal parts.

Uses

For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regurgitation) (See section 'Dosage and administration').

For the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter) in Doberman Pinschers following echocardiographic diagnosis of cardiac disease (see section 'Contra-indications, warnings, etc').

For the treatment of dogs with myxomatous mitral valve disease (MMVD) in the preclinical stage (asymptomatic with a systolic mitral murmur and evidence of increased heart size) to delay the onset of clinical symptoms of heart failure (see section 'Contra-indications, warnings, etc').

Dosage and administration

Determine the bodyweight accurately before treatment to ensure correct dosage.

A dosage range of 0.2 mg to 0.6 mg pimobendan/kg body weight, divided into two daily doses, should be respected.

The preferable daily dose is 0.5 mg pimobendan/kg body weight, divided into two daily doses.

For a body weight of 5 kg, this corresponds to one 1.25 mg chewable tablet in the morning and one 1.25 mg chewable tablet in the evening.

For a body weight of 20 kg, this corresponds to one 5 mg chewable tablet in the morning and one 5 mg chewable tablet in the evening.

For a body weight of 40 kg, this corresponds to one 10 mg chewable tablet in the morning and one 10 mg chewable tablet in the evening.

Do not exceed the recommended dosage.

Pimobendan is orally administered. Administration of pimobendan should take place approximately one hour before feeding.

Pimobendan may also be used in combination with a diuretic, e.g. furosemide.

To allow accurate dosing according to body weight, the chewable tablet can be halved along the designated score line.

Contra-indications, warnings, etc

Do not use pimobendan in hypertrophic cardiomyopathies or in diseases in which an improvement in cardiac output cannot be achieved for functional or anatomical reasons (e.g. aortic stenosis). Since pimobendan is metabolised mainly via the liver, it should not be used in dogs with severe impairment of liver function.

The product has not been tested in cases of asymptomatic DCM in Dobermans with atrial fibrillation or sustained ventricular tachycardia.

The product has not been tested in cases of asymptomatic myxomatous mitral valve disease in dogs with significant supraventricular and/or ventricular tachyarrhythmia.

The blood glucose should be tested regularly during treatment in dogs with existing diabetes mellitus.

For use in the “preclinical stage” of dilated cardiomyopathy (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter), a diagnosis should be made by means of a comprehensive cardiac examination (incl. echocardiographic examination and possibly Holter monitoring).

For use in the preclinical stage of myxomatous mitral valve disease (stage B2, according to ACVIM consensus: asymptomatic with mitral murmur ≥3/6 and cardiomegaly due to myxomatous mitral valve disease), a diagnosis should be made by means of a comprehensive physical and cardiac examination which should include echocardiography or radiography where appropriate. (See also 'Further Information' section).

Monitoring of cardiac function and morphology is recommended in animals treated with pimobendan.

The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of animals.

In rare cases a slight positively chronotropic effect (rise in heart rate) and vomiting can occur. However, these effects are dose-dependent and can be avoided by reducing the dose.

In rare cases transient diarrhoea, anorexia or lethargy have been observed.

In rare cases, an increase in mitral valve regurgitation has been observed during chronic pimobendan treatment in dogs with mitral valve disease.

Although a relationship with pimobendan has not been clearly established, in very rare cases, signs of effects on primary haemostasis (petechiae on mucous membranes, subcutaneous haemorrhages) may be observed during treatment. These signs disappear when the treatment is withdrawn.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Laboratory studies in rats and rabbits have not produced any evidence of teratogenic or foetotoxic effects. However, these studies have shown evidence of maternotoxic and embryotoxic effects at high doses, and have also shown that pimobendan is excreted into milk. The safety of the product has not been assessed in pregnant or nursing bitches. Use only according to the benefit/risk assessment by the responsible veterinarian.

In pharmacological studies no interaction between the cardiac glycoside strophanthin and pimobendan was observed. The pimobendan-induced increase in cardiac contractility is attenuated by the calcium antagonists verapamil and diltiazem and by the β-antagonist propranolol.

An overdose may cause a positive chronotropic effect, vomiting, apathy, ataxia, heart murmurs or hypotension. In this situation, the dosage should be reduced and appropriate symptomatic treatment should be initiated.

In prolonged exposure (6 months) of healthy beagle dogs at 3 and 5 times the recommended dose, mitral valve thickening and left ventricular hypertrophy were observed in some dogs. These changes are of pharmacodynamic origin.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

Advice to doctors: accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches.

Pharmaceutical precautions

Shelf life of the veterinary medicinal product as packaged for sale: 30 months

Shelf life of the divided (halved) tablets after opening the immediate packaging: 3 days

Do not store above 25°C.

Divided tablets should be returned to the open blister pocket and placed back in the cardboard box.

Keep out of sight and reach of children. For animal treatment only.

To be supplied only on veterinary prescription.

Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Legal category

Packaging quantities

Heat sealed Aluminium// PVC/ Aluminium/ Polyamide blister strip containing 10 tablets.

Cardboard box with 2 blister strips of 10 tablets (20 tablets)

Cardboard box with 5 blister strips of 10 tablets (50 tablets)

Cardboard box with 10 blister strips of 10 tablets (100 tablets)

Not all packs sizes may be marketed.

Marketing Authorisation Holder (if different from distributor)

Further information

Pimobendan, a benzimadazole-pyridazinone derivative has a positively inotropic action and possesses pronounced vasodilator properties.

The positive inotropic effect of pimobendan is mediated by two action mechanisms: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase III. Thus the positive inotropism is triggered neither by an action similar to that of the cardiac glycosides nor sympathomimetically.

The vasodilator effect arises from inhibition of phosphodiesterase III.

When used in cases of symptomatic valvular insufficiency in conjunction with furosemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs.

When used in a limited number of cases of symptomatic dilated cardiomyopathy in conjunction with furosemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.

In a randomized and placebo controlled study in 363 dogs with preclinical myxomatous mitral valve disease, all dogs met the following inclusion criteria: age ≥ 6 years, bodyweight ≥ 4.1 and ≤ 15 kg, characteristic systolic heart murmur of moderate to high intensity (≥grade 3/6) with maximal intensity over the mitral area; echocardiographic evidence of advanced myxomatous mitral valve disease (MMVD) defined as characteristic valvular lesions of the mitral valve apparatus, echocardiographic evidence of left atrial and left ventricular dilatation and radiographic evidence of cardiomegaly (vertebral heart sum (VHS) > 10.5. The median time to onset of clinical signs of heart failure or cardiac death/euthanasia was extended in these dogs by approximately 15 months. Additionally, there was a reduction in the heart size of dogs treated with pimobendan in the preclinical stage of myxomatous mitral valve disease. Furthermore, overall survival time was prolonged by approximately 170 days in all dogs receiving pimobendan independent of their cause of death (cardiac death/ euthanasia and non-cardiac death/euthanasia). Cardiac related death or euthanasia occurred in 15 dogs in the pimobendan group and 12 dogs in the placebo group prior to the onset of CHF. Dogs in the pimobendan group spent a longer time in the study (347.4 patient years) than those in the placebo group (267.7 patient years) resulting in a lower rate of occurrence.

In a randomized and placebo controlled study including Doberman Pinschers with preclinical dilated cardiomyopathy (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter following echocardiographic diagnosis), the time to onset of congestive heart failure or sudden death was extended and survival time was prolonged among dogs administered pimobendan.

Additionally, there was a reduction in the heart size of dogs treated with pimobendan in the preclinical stage of dilated cardiomyopathy. Efficacy evaluation is based on data from 19 (of 39) and 25 (of 37) dogs that reached the primary efficacy endpoint in the pimobendan and the placebo group, respectively.

Absorption: After oral administration of this veterinary medicinal product the absolute bioavailability of its active substance is 60 - 63%. Since simultaneous or previous food intake reduces the bioavailability, pimobendan should be administered about 1 hour before feeding.

Distribution: The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93%.

Metabolism: The compound is demethylated by oxidation to the major active metabolite (UD-CG212). Further metabolic steps are phase II conjugates of UD-CG212, such as glucuronides and sulphates.

Elimination:The plasma elimination half-life of pimobendan is 0.4 ± 0.1 hours, which corresponds to the high clearance of 90 ± 19 ml/min/kg and the short mean residence of 0.5 ± 0.1 hours.

The most significant active metabolite is eliminated with a plasma elimination half-life of 2.0 ± 0.3 hours. Almost the entire dose is eliminated in the faeces.

Marketing Authorisation Number

Vetmedin Chew 1.25 mg chewable tablets for dogs: Vm 00015/4091

Vetmedin Chew 5 mg chewable tablets for dogs: Vm 00015/4093

Vetmedin Chew 10 mg chewable tablets for dogs: Vm 00015/4094

10mg Flavour Tablet » Priced per Tablet

Vetmedin Chew 1.25 mg, 5 mg and 10 mg chewable tablets for dogs

Presentation

Chewable tablet.

Brownish, oval, divisible tablet, scored on both sides.

One 1.25 mg chewable tablet contains 1.25 mg pimobendan as active substance.

One 5 mg chewable tablet contains 5 mg pimobendan as active substance.

One 10 mg chewable tablet contains 10 mg pimobendan as active substance.

The tablets can be divided into equal parts.

Uses

For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regurgitation) (See section 'Dosage and administration').

For the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter) in Doberman Pinschers following echocardiographic diagnosis of cardiac disease (see section 'Contra-indications, warnings, etc').

For the treatment of dogs with myxomatous mitral valve disease (MMVD) in the preclinical stage (asymptomatic with a systolic mitral murmur and evidence of increased heart size) to delay the onset of clinical symptoms of heart failure (see section 'Contra-indications, warnings, etc').

Dosage and administration

Determine the bodyweight accurately before treatment to ensure correct dosage.

A dosage range of 0.2 mg to 0.6 mg pimobendan/kg body weight, divided into two daily doses, should be respected.

The preferable daily dose is 0.5 mg pimobendan/kg body weight, divided into two daily doses.

For a body weight of 5 kg, this corresponds to one 1.25 mg chewable tablet in the morning and one 1.25 mg chewable tablet in the evening.

For a body weight of 20 kg, this corresponds to one 5 mg chewable tablet in the morning and one 5 mg chewable tablet in the evening.

For a body weight of 40 kg, this corresponds to one 10 mg chewable tablet in the morning and one 10 mg chewable tablet in the evening.

Do not exceed the recommended dosage.

Pimobendan is orally administered. Administration of pimobendan should take place approximately one hour before feeding.

Pimobendan may also be used in combination with a diuretic, e.g. furosemide.

To allow accurate dosing according to body weight, the chewable tablet can be halved along the designated score line.

Contra-indications, warnings, etc

Do not use pimobendan in hypertrophic cardiomyopathies or in diseases in which an improvement in cardiac output cannot be achieved for functional or anatomical reasons (e.g. aortic stenosis). Since pimobendan is metabolised mainly via the liver, it should not be used in dogs with severe impairment of liver function.

The product has not been tested in cases of asymptomatic DCM in Dobermans with atrial fibrillation or sustained ventricular tachycardia.

The product has not been tested in cases of asymptomatic myxomatous mitral valve disease in dogs with significant supraventricular and/or ventricular tachyarrhythmia.

The blood glucose should be tested regularly during treatment in dogs with existing diabetes mellitus.

For use in the “preclinical stage” of dilated cardiomyopathy (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter), a diagnosis should be made by means of a comprehensive cardiac examination (incl. echocardiographic examination and possibly Holter monitoring).

For use in the preclinical stage of myxomatous mitral valve disease (stage B2, according to ACVIM consensus: asymptomatic with mitral murmur ≥3/6 and cardiomegaly due to myxomatous mitral valve disease), a diagnosis should be made by means of a comprehensive physical and cardiac examination which should include echocardiography or radiography where appropriate. (See also 'Further Information' section).

Monitoring of cardiac function and morphology is recommended in animals treated with pimobendan.

The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of animals.

In rare cases a slight positively chronotropic effect (rise in heart rate) and vomiting can occur. However, these effects are dose-dependent and can be avoided by reducing the dose.

In rare cases transient diarrhoea, anorexia or lethargy have been observed.

In rare cases, an increase in mitral valve regurgitation has been observed during chronic pimobendan treatment in dogs with mitral valve disease.

Although a relationship with pimobendan has not been clearly established, in very rare cases, signs of effects on primary haemostasis (petechiae on mucous membranes, subcutaneous haemorrhages) may be observed during treatment. These signs disappear when the treatment is withdrawn.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Laboratory studies in rats and rabbits have not produced any evidence of teratogenic or foetotoxic effects. However, these studies have shown evidence of maternotoxic and embryotoxic effects at high doses, and have also shown that pimobendan is excreted into milk. The safety of the product has not been assessed in pregnant or nursing bitches. Use only according to the benefit/risk assessment by the responsible veterinarian.

In pharmacological studies no interaction between the cardiac glycoside strophanthin and pimobendan was observed. The pimobendan-induced increase in cardiac contractility is attenuated by the calcium antagonists verapamil and diltiazem and by the β-antagonist propranolol.

An overdose may cause a positive chronotropic effect, vomiting, apathy, ataxia, heart murmurs or hypotension. In this situation, the dosage should be reduced and appropriate symptomatic treatment should be initiated.

In prolonged exposure (6 months) of healthy beagle dogs at 3 and 5 times the recommended dose, mitral valve thickening and left ventricular hypertrophy were observed in some dogs. These changes are of pharmacodynamic origin.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

Advice to doctors: accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches.

Pharmaceutical precautions

Shelf life of the veterinary medicinal product as packaged for sale: 30 months

Shelf life of the divided (halved) tablets after opening the immediate packaging: 3 days

Do not store above 25°C.

Divided tablets should be returned to the open blister pocket and placed back in the cardboard box.

Keep out of sight and reach of children. For animal treatment only.

To be supplied only on veterinary prescription.

Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Legal category

Packaging quantities

Heat sealed Aluminium// PVC/ Aluminium/ Polyamide blister strip containing 10 tablets.

Cardboard box with 2 blister strips of 10 tablets (20 tablets)

Cardboard box with 5 blister strips of 10 tablets (50 tablets)

Cardboard box with 10 blister strips of 10 tablets (100 tablets)

Not all packs sizes may be marketed.

Marketing Authorisation Holder (if different from distributor)

Further information

Pimobendan, a benzimadazole-pyridazinone derivative has a positively inotropic action and possesses pronounced vasodilator properties.

The positive inotropic effect of pimobendan is mediated by two action mechanisms: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase III. Thus the positive inotropism is triggered neither by an action similar to that of the cardiac glycosides nor sympathomimetically.

The vasodilator effect arises from inhibition of phosphodiesterase III.

When used in cases of symptomatic valvular insufficiency in conjunction with furosemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs.

When used in a limited number of cases of symptomatic dilated cardiomyopathy in conjunction with furosemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.

In a randomized and placebo controlled study in 363 dogs with preclinical myxomatous mitral valve disease, all dogs met the following inclusion criteria: age ≥ 6 years, bodyweight ≥ 4.1 and ≤ 15 kg, characteristic systolic heart murmur of moderate to high intensity (≥grade 3/6) with maximal intensity over the mitral area; echocardiographic evidence of advanced myxomatous mitral valve disease (MMVD) defined as characteristic valvular lesions of the mitral valve apparatus, echocardiographic evidence of left atrial and left ventricular dilatation and radiographic evidence of cardiomegaly (vertebral heart sum (VHS) > 10.5. The median time to onset of clinical signs of heart failure or cardiac death/euthanasia was extended in these dogs by approximately 15 months. Additionally, there was a reduction in the heart size of dogs treated with pimobendan in the preclinical stage of myxomatous mitral valve disease. Furthermore, overall survival time was prolonged by approximately 170 days in all dogs receiving pimobendan independent of their cause of death (cardiac death/ euthanasia and non-cardiac death/euthanasia). Cardiac related death or euthanasia occurred in 15 dogs in the pimobendan group and 12 dogs in the placebo group prior to the onset of CHF. Dogs in the pimobendan group spent a longer time in the study (347.4 patient years) than those in the placebo group (267.7 patient years) resulting in a lower rate of occurrence.

In a randomized and placebo controlled study including Doberman Pinschers with preclinical dilated cardiomyopathy (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter following echocardiographic diagnosis), the time to onset of congestive heart failure or sudden death was extended and survival time was prolonged among dogs administered pimobendan.

Additionally, there was a reduction in the heart size of dogs treated with pimobendan in the preclinical stage of dilated cardiomyopathy. Efficacy evaluation is based on data from 19 (of 39) and 25 (of 37) dogs that reached the primary efficacy endpoint in the pimobendan and the placebo group, respectively.

Absorption: After oral administration of this veterinary medicinal product the absolute bioavailability of its active substance is 60 - 63%. Since simultaneous or previous food intake reduces the bioavailability, pimobendan should be administered about 1 hour before feeding.

Distribution: The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93%.

Metabolism: The compound is demethylated by oxidation to the major active metabolite (UD-CG212). Further metabolic steps are phase II conjugates of UD-CG212, such as glucuronides and sulphates.

Elimination:The plasma elimination half-life of pimobendan is 0.4 ± 0.1 hours, which corresponds to the high clearance of 90 ± 19 ml/min/kg and the short mean residence of 0.5 ± 0.1 hours.

The most significant active metabolite is eliminated with a plasma elimination half-life of 2.0 ± 0.3 hours. Almost the entire dose is eliminated in the faeces.

Marketing Authorisation Number

Vetmedin Chew 1.25 mg chewable tablets for dogs: Vm 00015/4091

Vetmedin Chew 5 mg chewable tablets for dogs: Vm 00015/4093

Vetmedin Chew 10 mg chewable tablets for dogs: Vm 00015/4094

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews (200)

Q & A

Below are some recent questions we've received regarding Vetmedin for Dogs, including answers from our team.

9 February 2018 at 8:59am

Ventmedin 1.25 capsules

ingrid

hi just wondering if we can break the capsule and place the ingredients inside into some water and syringe to insert into our dogs mouth as she finds it hard to swallow it and we have a hard time getting it down her throat. which actually causes more stress to our dog.

  • Veterinary Advisor

Drugs are generally made in a capsule for a reason, which is usually to protect the active ingredient in the stomach acid so that it can reach the small intestine where it is absorbed. I would be concerned that the drug would not be as effective if you were to mix the powder with water and syringe it in. Vetmedin is available in a tablet form if you think that this would be easier (your vet would need to write a prescription for tablets not capsules for us to dispense these).

16 September 2015 at 11:36pm

Change of dosage

Joanne

My dog has been on vetmedin for 6 months now and last week the vet and I decided to cut the dosage down to 1 a day purely for fianacel reasons. She seems to be a more sleepy and lethargic I'm thinking she needs to go back on the second one again would you say so as well ?

  • Non-Executive Director

This drug only persists in the body for a few hours and twice daily dosing is likely to be much better than once daily. Regardless of that you should always give it on an empty stomach and with no food for at least 30 minutes afterwards if possible, because it is not easily absorbed into the body and any food present will reduce this further, reducing its effect. I would suggest going for twice daily if possible. You might find that if you can do the empty stomach bit very well, you could reduce the amount of each dose slightly to make it cheaper. Other than that it might be possible to add some other heart treatments which work well alongside Vetmedin but are cheaper (frusemide and digoxin for example). You must talk to your vet about them and they can have some side effects, but again at a lowish dose they are beneficial and safe. They are much cheaper than Vetmedin.

15 December 2014 at 5:17pm

Vetmedin

dave

Once started on vetmedin can you stop the treatment then restart or should it be given continuel without a break

  • Non-Executive Director

Most dogs treated with this medication benefit significantly from from it. If the drug is then stopped, they lose this benefit and go back to approximately how they were before. The would not be expected to be worse off, but given the benefit they receive when on the drug, it would be a shame to take this away.

16 December 2013 at 12:36pm

Using Vetmedin for heart trouble

Hayley Baines

I'm looking for some advice, my dog is currently on Vetmedin 5mg Flavour Tablets and have noticed that she seems to feel the cold as she sits and shivers just wondered if this was a side effect and also what other side effects could this medication cause? also reading the information leaflet it's advised that the tablet should be given half in the morning then the other half 12 hours later? Both an hr before food? however my vet has said one tablet half an hour before food so I am slightly confused as i don't want to be miss dosing my dog?

  • Non-Executive Director

Vetmedin is a very safe drug. It is most likely that your dog feels the cold because she is getting a bit older and less robust. I would doubt if the Vetmedin is doing that.

It is usual to give Vetmedin twice daily. In fact most of the drug is passed out of the system in just a few hours, so twice a day makes a lot more sense. It is also not absorbed very well from the stomach if there is food there too. 30-60 minutes before feeding is often recommended, but closer to 60 would seem better if you can manage it. Vetmedin is possibly the most useful drug there is for many heart problems, so it is well worth getting right if you can. The amount given on each occasion is based on the weight of your dog. It is always best to ask your own vet about the precise amount to give, which should be decided after weighing your dog.

19 October 2013 at 3:54am

Use by date on drugs

Sue Harris

  • VioVet customer since 2013
  • From: VIC, Australia

Hi, with regards to the Fortekor and Vetmedin drugs i wanted to find out how long of a use by date they come with, as i need a minimum 12 month use by date.

  • Brand Manager

We have a high turn over of these products and deliveries are received daily, so you should normally expect to receive a product with a good length expiry date. Our supplier will continue to deliver a particular batch to us until they have all been used up, so occasionally the date may be slightly shorter than you require. If you would like to place an order for a long-term supply, you are welcome to contact our customer service team who will be able to tell you the expiry dates of batches in stock at the time. At present (21/10/13) the shortest expiry date we have for these products is 01/2015.

Alternatively, if it is convenient, you can place a few smaller orders for the prescribed medication, as we keep your prescription details and number of medication on our system. Once a prescription is has been loaded by our staff, you can log in to your VioVet account and check your amount remaining in the "Prescriptions" section.